By week six I was at 162 lb without counting a single calorie
Stanford noted factors such as effectiveness, adherence, and affordability playing a role in how quickly and broadly GLP-1 pills are adopted once available
There were no differences between the groups in trabecular MAR ([95% CI 0.3 to 0.6]: p = 0.836), cortical MAR ([95% CI 0.7 to 0.5]: p = 0.382), trabecular MS/BS ([95% CI 1.7 to 6.2]: p = 0.318), cortical MS/BS ([95% CI 8.4 to 4.6]: p = 0.791), trabecular BFR ([95% CI 2.1 to 4.6]: p = 0.480), or cortical BFR ([95% CI 13.7 to 3.2]: p = 0.836) (Table 2)
Monitoring the right biomarkers while on a GLP-1 helps you and your provider ensure youre losing fat not muscle
Brouwers B, Rao G, Tang Y et al (2024) Incretin-based investigational therapies for the treatment of MASLD/MASH